Breaking News, Promotions & Moves

SK Pharmteco Names David Lowndes as Chief Operating Officer

Lowndes will lead the company’s global Supply Chain, Quality, Regulatory Affairs, R&D, IT/Digital, and Operational Excellence functions.

SK pharmteco, a global contract development and manufacturing organization serving the pharmaceutical industry, has appointed David Lowndes as Chief Operating Officer.
 
Lowndes will lead the company’s global Supply Chain, Quality, Regulatory Affairs, R&D, IT/Digital, and Operational Excellence functions.
 
“After serving together on multiple Pharma company Boards of Directors, it is with pleasure to announce that David has agreed to join the SK pharmteco Leadership Team as Chief Operating Officer. David brings a wealth of experience across the pharmaceutical industry and will provide leadership to the patient-centric focus we continually strive for by ensuring functional excellence in everything we do,” shares Joerg Ahlgrimm, CEO of SK pharmteco.

About David Lowndes

Lowndes brings 38 years of experience and a track record of delivering world-class results across multiple corporate leadership roles. Most recently, he served on the Board of Directors of SK pharmteco and was a Senior Vice President at SHIRE Pharmaceuticals, where he oversaw multiple global functions.
 
“SK pharmteco is entering a period of exceptional growth, and I am excited to serve as a member of the Corporate Leadership Team driving our company to the next level. Our vision is to be the most trusted partner in the manufacture and testing of medicines and through this, benefit patients and society worldwide,” shares Lowndes.
 
Lowndes holds a bachelor’s degree in Pharmacy from Cardiff University in Wales. He has served on numerous professional communities, including the Faculty of Supply Chain Management World, the Future of Healthcare Advisory Board – Supply Chain Management World, the Governance Committee/Xavier Integrity of Supply Initiative, and a member of the strategy committee at the FDA/Xavier Pharmalink conference.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters